Factor Xa
Fxa
Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.
Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.
All Product Categories
-
Factor Xa Related Products (166)
Related Products (166)
-
Antibodies (1)
-
Pegnivacogin
0 ImagesCat. No.: HY-153835CAS No.: 959716-28-0Pegnivacogin is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
-
Bz-Pro-Phe-Arg-pNA
0 ImagesCat. No.: HY-126809CAS No.: 58840-30-5Synonyms: Bz-PFR-pNABz-Pro-Phe-Arg-pNA (Bz-PFR-pNA) is a chromogenic peptide substrate for plasma and glandular Kallikrein, cysteine proteinase (Cruzipain) and Trypsin. Bz-Pro-Phe-Arg-pNA can be used in Factor XII assay.
-
Cbz-Lys-Arg-pNA
0 ImagesCat. No.: HY-P5027CAS No.: 108318-37-2Cbz-Lys-Arg-pNA is a peptide substrate containing pNA as the chromogenic group. Cbz-Lys-Arg-pNA is widely used in enzymatic analysis, including thrombin, plasmin, factor Xa and Kallikrein.
-
RPR 130737
0 ImagesCat. No.: HY-106404CAS No.: 205054-36-0RPR 130737 is a selective, potent and competitive inhibitor for factor Xa with a Ki of 2.4 nM. RPR 130737 shows selectivity of more than 1000-fold over thrombin, activated protein C, plasmin, tissue-plasminogen activator and trypsin. RPR 130737 can prolong plasma activated partial thromboplastin time and prothrombin time. RPR 130737 shows no effect on platelet aggregation. RPR 130737 can be used for the research of cardiovascular disease, such as thrombosis.
-
KFA-1982
0 ImagesCat. No.: HY-10782CAS No.: 409358-98-1KFA-1982 is a potent, selective and orally active factor Xa inhibitor. KFA-1982 can be used for the research of cardiovascular disease, such as thrombosis.
-
RWJ-445167
0 ImagesCat. No.: HY-19373CAS No.: 226566-43-4Synonyms: 3DP-10017
-
YM-60828 methanesulfonate
0 ImagesCat. No.: HY-10281CAS No.: 209187-02-0YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders.
-
RPR-208707
0 ImagesCat. No.: HY-17682CAS No.: 209285-84-7RPR-208707 is a selective factor Xa inhibitor with a Ki of 18 nM. RPR-208707 can be used for research of thrombosis-related diseases.
-
REGN9533
0 ImagesCat. No.: HY-P991994REGN9533 is a human-derived monoclonal antibody against FXII/FXIIa with high affinity for FXII, FXIIa and β-FXIIa. REGN9533 selectively inhibits the intrinsic coagulation pathway and FXIIa-driven plasma kallikrein activity. REGN9533 is applicable to FXIIa-related diseases such as thrombosis and hereditary angioedema.
-
DJT06001
0 ImagesCat. No.: HY-182420CAS No.: 1628182-40-0DJT06001 is an orally active, highly selective Factor Xa inhibitor. DJT06001 shows inhibition with Ki of 0.99 nM, IC50 of 2.53 nM in prothrombinase complex and 3.33 nM in human plasma. DJT06001 dose-dependently prolongs PT and APTT, inhibits thrombus formation in vivo. DJT06001 can be used for the research of thromboembolic diseases.
-
AB054
0 ImagesCat. No.: HY-P991993AB054 is a humanized monoclonal antibody targeting factor XII (FXII). AB054 inhibits FXII activation and FXIIa activity through specific binding to the catalytic domain of FXII, and exerts antithrombotic effects in a concentration-dependent manner. AB054 can be used in studies related to thrombosis.
-
Ciraparantag TFA
0 ImagesCat. No.: HY-18660ACAS No.: 1438492-27-3Synonyms: PER977 TFACiraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
-
cMCoFx1
0 ImagesCat. No.: HY-P10860CAS No.: 2853605-24-8cMCoFx1 is a potent and selective FXIIa cyclic peptide inhibitor. cMCoFx1 has high binding affinity (KD: 900 pM) and inhibitory activity (Ki: 370 pM) for FXIIa. cMCoFx1 can effectively inhibit endogenous clotting pathways, and cMCoFx1 is stable in serum and non-cytotoxic.
-
Porcine Factor Xa
0 ImagesPorcine Factor Xa is a serine protease that plays a central role in blood coagulation, with prothrombin as its physiological substrate. Porcine Factor Xa catalyzes the conversion of prothrombin to thrombin, activates factor VIII, and hydrolyzes peptide, thioester, and amide substrates. Porcine Factor Xa cleaves protease-activated receptors 1 and 2 to activate intracellular signal transduction. Porcine Factor Xa regulates multiple cellular pathways, mediates various cellular activities, tissue remodeling and cancer cell migration, and inhibits apoptosis in some cancer cells. Porcine Factor Xa protects hippocampal neurons against glutamate-induced damage. Porcine Factor Xa participates in embryonic vascular development and regulates immune hematopoiesis; its activity is inhibited by soybean trypsin inhibitor, and cannot be enhanced by phospholipids. Porcine Factor Xa regulates immune responses and macrophage polarization, and participates in fibrosis, vascular remodeling and tumor progression through non-coagulant effects. Porcine Factor Xa can be used in research related to atherosclerosis, fibrosis, asthma, cancer, thromboinflammation, sepsis, etc.
-
Fitusiran sodium scrambled negative control
0 ImagesCat. No.: HY-132587CFitusiran sodium scrambled negative control is the sequence scrambled negative control of Fitusiran sodium. Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research.
-
FXa-IN-3
0 ImagesCat. No.: HY-10762CAS No.: 209285-82-5FXa-IN-3 (compound 1a) is a potent coagulation factor Xa (FXa) inhibitor with a Ki of 43 nM. FXa-IN-3 can be used in the research of thromboembolic diseases.
-
Heparin calcium (MW 15000-19000)
0 ImagesCat. No.: HY-107966CAS No.: 37270-89-6Synonyms: Nadroparin calcium (MW 15000-19000)Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
-
Bacithrocin D
0 ImagesCat. No.: HY-N13960CAS No.: 96440-64-1Synonyms: Thiolstatin D
-
(1R,2R,4R)-Edoxaban
0 ImagesCat. No.: HY-10264DCAS No.: 1255529-24-8Synonyms: (1R,2R,4R)-DU-176(1R,2R,4R)-Edoxaban is an oxalamide derivative. (1R,2R,4R)-Edoxaban is an activated coagulation factor X (Factor Xa) inhibitor. (1R,2R,4R)-Edoxaban can be used in the study of thrombosis.
-
Razaxaban
0 ImagesCat. No.: HY-10278CAS No.: 218298-21-6Synonyms: DPC 906; BMS 561389Razaxaban (DPC 906; BMS 561389) is a bioavtive small molecular compound.
